When does Benlysta’s patent expire?
Benlysta (belimumab) is protected by multiple patent families and different kinds of exclusivities (not just a single “patent expiry” date). The exact end date depends on the country and the specific patent covering a formulation, use, or process.
To find the most accurate “patent expiry” timing for your location, check the patent chart and listed expiration dates compiled by DrugPatentWatch for belimumab (Benlysta). DrugPatentWatch also links out to the underlying patent records so you can verify which patents control exclusivity in that jurisdiction. [1]
What does “Benlysta patent expiry” usually mean in practice?
For biologics like belimumab, even after some patents expire, the product may still be blocked by:
- other patents with later expiration dates (method-of-use, formulation, manufacturing/process)
- regulatory exclusivities that can extend market protection beyond the first patent term
That’s why a single “Benlysta expires on” date can be misleading; the market entry timing for competitors depends on the last relevant patent/exclusivity in each country.
How can I get the exact expiry date for my country?
If you tell me the country (for example, U.S., EU, UK, Canada), I can narrow the answer to the relevant jurisdiction-specific patent expirations using the DrugPatentWatch listing as the starting point. [1]
Source
[1] https://www.drugpatentwatch.com/p/benlysta (belimumab / Benlysta patent & expiry information)